Skip to main content

Table 2 Comparison of other genetic alterations between AML patients in low and high BDH2 expression groups

From: Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia

Variant Number of patients with the gene alternation (percentage) P
Whole cohort Low BDH2, expression High BDH2, expression
NPM1 mut 36 (31.85%) 16 (28.07%) 20 (35.71%) 0.271
FLT3- ITD 23 (20.35%) 7 (12.28%) 16 (28.57%) 0.030*
FLT3- TKD 8 (7.08%) 5 (8.77%) 3 (5.36%) 0.338
NPM1mut/FLT3- ITDneg 20 (17.70%) 11(19.30%) 9 (16.07%) 0.368
CEBPA a 34 (30.09%) 16 (28.07%) 18 (32.14%) 0.444
CEBPA Double mutation 9 (7.96%) 3 (5.26%) 6 (10.71%) 0.593
IDH1 b 3 (3.75 %) 1 (2.56 %) 2 (4.88%) 0.592
IDH2 b 8 (10 %) 3 (7.69%) 5 (12.20%) 0.508
DNMT3A b 12 (15 %) 10 (25.641%) 2 (4.88%) 0.009*
MLL b 7 (8.75%) 3 (7.69%) 4 (9.76%) 0.426
ERG c 11.17 (10.26-12.08) 11.60 (10.48-12.72) 10.68 (9.17-12.20) 0.320
MN1 c 12.98 (12.28-13.68) 13.35 (12.42-14.28) 12.55 (11.47-13.64) 0.257
miR-181a c 3.12 (2.57-3.67) 3.17 (2.35-3.98) 3.07 (2.30-3.84) 0.864
miR-3151 c 12.35 (11.90-12.80) 12.18 (11.53-12.84) 12.53 (11.89-13.16) 0.448
  1. Values are number (%) of patients with alteration.
  2. aCEBPAsingle and double mutations.
  3. bOnly 80 patients with high quality of DNA to sequence; 39 patients are low BDH2 expression and 41 patients are high expression.
  4. cMean (95% CI).
  5. *Statistically significant (P < 0.05).